Chemokine expands protection of core anti-cancer technology with issuance of new United States patent.Chemokine chemokine /che·mo·kine/ (ke´mo-kin) any of a group of low molecular weight cytokines identified on the basis of their ability to induce chemotaxis or chemokinesis in leukocytes (or in particular populations of leukocytes) in inflammation. Therapeutics Corporation (Vancouver, Canada), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders blood disorders, n.pl hematologic dyscrasias that affect the component cells and plasma elements of the blood. They are generally divided into two broad groups: those in which an increase in bulk occurs (e.g. , cardiovascular, and infectious diseases, has been granted United States Patent 6,946,445 relating to a broad range of composition of matter claims, which include claims that cover its lead anti-cancer compound, CTCE-9908, among others. CTCE-9908 is designed to block CXCR CXCR Chemokine, CXC Motif, Receptor CXCR Alpha Chemokine Receptor 4, a receptor found on the surface of cancer cells. CTCE-9908 is part of a new generation of anti-cancer drug candidates that have the potential to both stop the spread of cancer (anti-metastasis) and slow the rate of cancer growth (anti-angiogenesis). The target receptor for CTCE-9908, CXCR4, is present on most tumors, including lung, breast, colon, ovarian, bone, brain and skin cancer cells. In experimental animal models, CTCE-9908 reduced cancer metastases Metastasis (plural, metastases) A tumor growth or deposit that has spread via lymph or blood to an area of the body remote from the primary tumor. Mentioned in: Malignant Melanoma by a significant 50-70%. The patent entitled "Therapeutic Chemokine Receptor Chemokine receptor A receptor on the surface of some types of immune cells that helps to mediate entry of HIV into the cell. Mentioned in: AIDS Antagonists", with a term lasting to March 2019, covers therapeutics compositions comprising CXCR4 receptor antagonists and builds on a patent granted earlier this year which focused on methods of use of the same compounds. The compositions are proteins that are comprised of amino acid amino acid (əmē`nō), any one of a class of simple organic compounds containing carbon, hydrogen, oxygen, nitrogen, and in certain cases sulfur. These compounds are the building blocks of proteins. sequences based on the natural human chemokine stromal cell derived factor-1 (SDF-1). The composition claims are further strengthened by reference to specific amino acid substitutions and the method by which active sequences of peptides are linked by a bridging segment. Chemokine scientists have developed hundreds of synthetic peptides using rational drug design with the goal of developing a new generation of drug candidates. In addition, the company has received confirmation that its contract manufacturer has successfully scaled up the production of CTCE-9908 in accordance with good manufacturing practices. This new lot of CTCE-9908 will be used for the company's Phase Ib/II clinical trials in cancer patients. Leading cancer researchers have demonstrated that high CXCR4 expression in cancer cells is correlated to tumor progression, high metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases 1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to rate and low survival rate. Blockage of CXCR4 reduces the growth of tumors by reducing blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. growth (anti-angiogenesis) which carries vital nutrients to a tumor. The company has completed a Phase I, dose-escalation clinical trial using CTCE-9908 in the United Kingdom to assess safety in healthy volunteers. CTCE-9908, after a single dose, was demonstrated to be safe and well tolerated by the study subjects. Chemokine is a product-focused biotechnology company developing drugs that harness the therapeutic potential of stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young through chemokine pathways. Chemokines are a class of proteins which signal biological responses from stem cells that play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection, as well as tissue repair and regeneration. Stem cells are the master primitive cells that give rise to all of the cells and organs in the body. Chemokines are one of the major mediators of stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. activity including stem cell growth, differentiation and maturation. Chemokine Therapeutics is a leader in research in this field. The company has five products with two lead product candidates in clinical trials; CTCE-0214, for enhancing the immune system, and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics Corporaation +1-604-827-3131 www.chemokine.net |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion